One reason pancreatic cancer is so lethal is its resistance to traditional chemotherapy. But West Virginia University surgical oncologist Brian Boone is exploring whether FOLFIRINOX–a new combination of cancer drugs–can improve outcomes in patients whose pancreatic cancer is “borderline resectable,” meaning that a tumor may be too close to a blood vessel to be removed safely. Read more . . .
If the American Cancer Society’s projections prove accurate, more people will die from pancreatic cancer than from breast, brain, ovarian or prostate cancer this year.